It is the brand name for an Oxford-AstraZeneca Covid-19 vaccine candidate known as AZD1222 or ChAdOx 1 nCoV19 in technical terms.
It is a variant of the vaccine produced by the University of Oxford in partnership with AstraZeneca, a Swedish-British pharmaceutical company.
The production partner in India is the Serum Institute of India (SII).
Action and Constituents:
It's based on a weaker variant of the common cold virus or the adenovirus that chimps carry.
The genetic material of the SARS-CoV-2 spike protein (protrusions) present on the virus's outer surface that assist it adhere to the human cell is contained in this viral vector.
This protein is meant to be recognised as a threat by the body's immune system, which will work to develop antibodies against it.
It is regarded one of the global frontrunners for the Covid-19 vaccine since it elicited an immunological response in people against the new coronavirus in early trials.
COVAXIN:
It is the only Covid-19 vaccine made in India.
Developed by Bharat Biotech, Hyderabad, in conjunction with the National Institute of Virology, Pune, of the Indian Council of Medical Research.
Action and Constituents:
It is an inactivated vaccine that is created by inactivating (killing) the disease-causing bacteria.
This disables the pathogen's ability to multiply while leaving it intact enough for the immune system to recognise it and mount an immunological response.
It's likely that it'll go after more than just the spike protein.
It also seeks to stimulate an immunological response against the nucleocapsid protein (the shell of the virus that encloses its genetic material).
COVAXIN contains immunogens (epitopes) from additional genes in addition to those from Spike protein, making it more likely to function against newer forms of the virus, including the UK variety.
Antigens are any material that binds uniquely to an antibody, whereas immunogens are any stimulus that causes a humoral or cell-mediated immune response.
Antigens and immunogens are both antigens, however not all antigens are immunogens.
COVAXIN's approval provides India with an extra vaccine protection, particularly against mutant strains in a dynamic pandemic situation.